Chongqing Zhifei Biological Products Co., Ltd.

Chongqing Zhifei Biological Products Co., Ltd. is a high-tech bio-pharmaceutical enterprise based in China, specializing in the research, development, production, sales, and distribution of vaccines and biological products. Established in 2002 and listed on the Shenzhen Stock Exchange in 2010, the company emphasizes a business principle that prioritizes social benefits over corporate profits. Zhifei is committed to addressing public health needs through innovative solutions, continually enhancing its capabilities in research and commercialization. The company's main business lines include the development and production of vaccines for infectious diseases such as influenza, cervical cancer, pneumonia, and tuberculosis. Zhifei has launched a diverse range of products, with a focus on both prevention and treatment. The company operates under a "production determined by sales" model, ensuring that production aligns with market demand. Through collaborations with research institutes and universities, Zhifei aims to enhance its innovation capacity and expand its market presence while adhering to stringent regulatory standards in pharmaceutical manufacturing.

As of the disclosure date of this report, a total of fifteen products had been launched, of which one product got conditional approval. The Company offers a diverse range of products, including vaccine products for preventing infectious diseases such as influenza, cervical cancer, pneumonia, influenza, rotavirus, herpes zoster and drugs for the diagnosis, prevention and treatment of Tuberculosis, to the public including groups of infants, teenagers and adults. In implementing the development model featuring "technology & market" drivers, the Company has formed a virtuous cycle where R&D and marketing promote each other to fast-track the entire process from R&D to the realization of market value. The Company has long been guided by the health needs of the people, adhering to its innovation strategy of "putting independent R&D at the core, conducting cooperative R&D as a backup, engaging in investment and incubation as a supplement." The Company is deeply engaged in the field of biopharmaceuticals and continuously improves its self-development capabilities. Company integrates resources and continues to increase R&D investment, lays out various development routes of vaccines, and gives full play to the synergistic effect of product matrices. Company sets its sights on investment and incubation of cutting-edge technologies, accelerating the transformation of scientific and technological achievements into quality products that serve people's health needs, accelerating the transformation of innovative technology into social benefits and commercial value. Company collaborates with leading research institutes, universities, and other organizations and sets its sights on investment and incubation of cutting-edge technologies. The Company actively engages in external cooperation in multiple areas and promotes collaborative innovation in the industry. Through capital operations, the Company continues to pool the internal and external resources of the Group and help the Listed Company acquire advanced R&D technologies, innovation patents, and high-quality products. These serve to enhance the Company's innovation capacity and expand its business presence, injecting more impetus into its sustained development. The Company implements the "production determined by sales" model, which is, the production department organizes production according to the marketing department's sales plan, and formulates a production schedule based on sales while also maintaining an appropriate inventory level. The Company strictly complies with the requirements of the Drug Administration Law of the People's Republic of China (hereinafter referred to as the "Drug Administration Law"), the Vaccine Administration Law of the People's Republic of China (hereinafter referred to as the "Vaccine Administration Law"), and the Regulations on the Administration of Vaccine Production and Circulation, among other pertinent laws and regulations. The Company ensures that its production and inspection strictly conforms to the approved production process and quality control standards, and that its entire production process complies with the good manufacturing practice requirements. The quality management department of the Company conducts strict supervision, inspection, and control over product quality. A complete production quality management system is in place to ensure that the entire production process meets ongoing compliance requirements. The Company employs a direct sales model. The Company's professional marketing team organizes academic meetings and promotional events, carries out activities to popularize vaccination knowledge to bring the Company's vaccines and medicines to end users. The Company's products are produced and sold in strict compliance with the Drug Administration Law, the Vaccine Administration Law, and other relevant laws and regulations, Implements strict management of the whole life cycle of products. Purchase contracts are signed based on the customer's needs. The products are mainly delivered to the designated locations through the Company's self-built storage and logistics system to complete the process of sales and settlement. According to laws and regulations, vaccines may be marketed and sold in their area of circulation only after they have been produced/imported and issued with batch release certificates by the state. Governments of provinces, autonomous regions, and municipalities can organize purchases of vaccine products via public resource trading platform at the provincial level. The Company distributes vaccine products to the disease prevention and control agencies or points of vaccination units designated by the disease prevention and control agency in accordance with procurement contracts.